AIM - AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO
AIM - AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.